Comparative Pharmacology
Head-to-head clinical analysis: CARMOL HC versus DESONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARMOL HC versus DESONATE.
CARMOL HC vs DESONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carmol HC is a combination of urea (a keratolytic) and hydrocortisone (a corticosteroid). Urea softens and dissolves the intercellular matrix of the stratum corneum, promoting desquamation and enhancing penetration of hydrocortisone. Hydrocortisone suppresses inflammation by induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
Apply a thin film to affected area twice daily; topical, not for ophthalmic or oral use.
Apply 0.05% cream, lotion, or ointment topically to affected skin twice daily.
None Documented
None Documented
1-2 hours (hydrocortisone acetate); clinical effects persist longer due to local anti-inflammatory action; tissue half-life not well defined.
Terminal half-life is approximately 3-4 hours for desonide; clinically, this supports twice-daily dosing.
Primarily renal excretion of metabolites (40-60%) as glucuronide and sulfate conjugates; <10% unchanged; biliary/fecal elimination accounts for <20%.
Renal (approximately 75% as metabolites, <5% unchanged) and fecal (approximately 25%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid